1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BeiGene, Ltd.
  6. News
  7. Summary
    BGNE   US07725L1026

BEIGENE, LTD.

(BGNE)
  Report
Real-time Estimate Cboe BZX  -  03:34 2022-08-19 pm EDT
175.56 USD   -1.28%
08/18Asian ADRs Move Lower in Thursday Trading
MT
08/15BeiGene, McKesson Unit to Collaborate to Improve Patient Access to Cancer Drugs
MT
08/15BeiGene Announces Strategic Alliance with Ontada to Improve U.S. Community Oncology Care
BU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Antengene Corporation Limited Announces Clinical Trial Collaboration with BeiGene, Ltd. to Evaluate Selinexor in Combination with Tislelizumab in T and NK-Cell Lymphoma

06/26/2022 | 08:30pm EDT

Antengene Corporation Limited announced that it has entered into a clinical trial collaboration with BeiGene to evaluate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of selinexor in combination with BeiGene's anti-PD-1 checkpoint inhibitor, tislelizumab. This multi-center, open-label Phase I/II trial will evaluate the investigational combination as a potential treatment option for patients with T and NK-cell lymphoma. Tislelizumab is a PD-1 inhibitor designed to help aid the body's immune cells to detect and fight tumors.

Tislelizumab, a humanized monoclonal antibody, is specifically designed to minimize binding to Fc?R on macrophages. In pre-clinical studies, binding to Fc?R on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells.


© S&P Capital IQ 2022
All news about BEIGENE, LTD.
08/18Asian ADRs Move Lower in Thursday Trading
MT
08/15BeiGene, McKesson Unit to Collaborate to Improve Patient Access to Cancer Drugs
MT
08/15BeiGene Announces Strategic Alliance with Ontada to Improve U.S. Community Oncology Car..
BU
08/15BeiGene Announces Strategic Alliance with Ontada to Improve U.S. Community Oncology Car..
CI
08/10BEIGENE : Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab ..
PU
08/10BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
08/10Asian ADRs Move Sharply Higher in Wednesday Trading
MT
08/09JPMorgan Assumes BeiGene at Overweight with $296 Price Target
MT
08/09Novartis-BeiGene Liver Cancer Drug Works As Well As Bayer's Nexavar in Phase 3 Study
MT
08/09BeiGene Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab..
BU
More news
Analyst Recommendations on BEIGENE, LTD.
More recommendations
Financials (USD)
Sales 2022 1 398 M - -
Net income 2022 -1 653 M - -
Net cash 2022 2 763 M - -
P/E ratio 2022 -14,5x
Yield 2022 -
Capitalization 18 400 M 18 400 M -
EV / Sales 2022 11,2x
EV / Sales 2023 8,03x
Nbr of Employees 8 600
Free-Float 99,0%
Chart BEIGENE, LTD.
Duration : Period :
BeiGene, Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BEIGENE, LTD.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Last Close Price 177,83 $
Average target price 274,75 $
Spread / Average Target 54,5%
EPS Revisions
Managers and Directors
John V. Oyler Director
Xiao Bin Wu President & Chief Operating Officer
Julia Wang Chief Financial & Accounting Officer
Lai Wang Global Head-Research & Development
Christiane Langer Senior Vice President-Global Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
BEIGENE, LTD.-34.36%18 400
GILEAD SCIENCES, INC.-10.23%81 694
VERTEX PHARMACEUTICALS34.01%75 473
REGENERON PHARMACEUTICALS, INC.-1.06%66 800
WUXI APPTEC CO., LTD.-23.44%38 898
BIONTECH SE-42.74%35 872